risankizumab

Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is...

UBS downgraded shares of AbbVie Inc (NYSE: ABBV), citing valuation and a likely delay in the U.S. biosimilar competition for Humira. Humira is AbbVie's best-selling drug approved to treat multiple indications such as rheumatoid arthritis, psoriatic arthritis and Crohn's disease, among others....

AbbVie Inc (NYSE: ABBV) disclosed that it presented a proof of concept, Phase II trial in Crohn's disease with investigatory biologic risankizumab, a compound from Boehringer Ingelheim research and recently licensed by the company. According to the company, Risankizumab was shown to be more...